pfizer glp-1 drug The next phase of the obesity race Structure Raises $300M as Oral
Description
Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)
We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity
Preclinical studies suggest that GIPR antagonism helps with weight loss and metabolic improvements
In this GLP1 capsule, every natural, premium ingredient works together to support optimal overall health
